NCT02207595

Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of UCB5857 in Healthy Subjects

A Randomized, Investigator- and Subject-blind, Placebo-controlled, Combined Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of UCB5857 in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: UCB Celltech · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The primary objective of this study is to investigate the safety and tolerability of UCB5857.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	UCB5857	* Active Substance: UCB5857 * Pharmaceutical Form: Capsule * Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg * Route of Administration: Oral Use
OTHER	Placebo	* Active Substance: Placebo * Pharmaceutical Form: Capsule * Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg * Route of Administration: Oral Use

Timeline

• Start date: 2014-08-01
• Primary completion: 2015-02-01
• Completion: 2015-02-01
• First posted: 2014-08-04
• Last updated: 2015-03-05

Locations

1 site across 1 country: United Kingdom